A new single-tablet HIV treatment combining bictegravir and lenacapavir has shown non-inferior efficacy compared to complex multi-drug regimens in a randomized phase 3 clinical trial. The ARTISTRY-1 study, published in The Lancet, evaluated the switch from complex HIV treatments to the simplified single-tablet regimen.
The simplified treatment approach addresses a significant challenge in HIV care, where patients often struggle with complex medication schedules involving multiple pills. Treatment adherence remains crucial for maintaining viral suppression and preventing drug resistance in HIV-1 patients.